VAPA and hepatocellular carcinoma: Importantly, treatment with N‐WASP inhibitor 187‐1‐packaged LOs (LOs/187‐1) dramatically abolishes the inductive effect of VAPA‐enriched LOs on pre‐metastatic niche formation and precludes HCC bone metastasis.